These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 10553701)

  • 1. Activity of newer fluoroquinolones in vitro against gram-positive bacteria.
    Eliopoulos GM
    Drugs; 1999; 58 Suppl 2():23-8. PubMed ID: 10553701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
    Hoogkamp-Korstanje JA; Roelofs-Willemse J
    J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of fluoroquinolones against gram-positive bacteria.
    Eliopoulos GM
    Drugs; 1995; 49 Suppl 2():48-57. PubMed ID: 8549407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance.
    Schmitz FJ; Higgins PG; Mayer S; Fluit AC; Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2002 Sep; 21(9):647-59. PubMed ID: 12373497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro antibacterial activity and pharmacodynamics of new quinolones.
    Dalhoff A; Schmitz FJ
    Eur J Clin Microbiol Infect Dis; 2003 Apr; 22(4):203-21. PubMed ID: 12687416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [In vitro susceptibility testing of 446 clinical isolates of gram-positive bacteria to new quinolones, carbapenems and cephalosporins].
    Cereda RF; Pignatari AC; Leme IL; Jones RN; Sader HS
    Rev Assoc Med Bras (1992); 1996; 42(3):130-4. PubMed ID: 9138353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of RWJ-54428 (MC-02,479) against multiresistant gram-positive bacteria.
    Chamberland S; Blais J; Hoang M; Dinh C; Cotter D; Bond E; Gannon C; Park C; Malouin F; Dudley MN
    Antimicrob Agents Chemother; 2001 May; 45(5):1422-30. PubMed ID: 11302805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.
    Barry AL; Fuchs PC; Brown SD
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1923-7. PubMed ID: 11353655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients.
    Rolston KV; Yadegarynia D; Kontoyiannis DP; Raad II; Ho DH
    Int J Infect Dis; 2006 May; 10(3):223-30. PubMed ID: 16439177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal surveillance on antibiogram of important Gram-positive pathogens in Southern China, 2001 to 2015.
    Xu Z; Xie J; Peters BM; Li B; Li L; Yu G; Shirtliff ME
    Microb Pathog; 2017 Feb; 103():80-86. PubMed ID: 27894963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of BAY Y3118, a new full-spectrum fluoroquinolone.
    Bremm KD; Petersen U; Metzger KG; Endermann R
    Chemotherapy; 1992; 38(6):376-87. PubMed ID: 1288961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone.
    Dalhoff A; Petersen U; Endermann R
    Chemotherapy; 1996; 42(6):410-25. PubMed ID: 8957575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment.
    Sparo MD; Jones DG; Sánchez Bruni SF
    Chemotherapy; 2009; 55(4):270-7. PubMed ID: 19494489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro ciprofloxacin resistance patterns of gram-positive bacteria isolated from clinical specimens in a teaching hospital in Saudi Arabia.
    Akhtar N; Alzahrani A; Obeid Oel-T; Dassal D
    J Ayub Med Coll Abbottabad; 2009; 21(3):54-6. PubMed ID: 20929013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.